STATE STREET CORP - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 1 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
STATE STREET CORP ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q4 2018$27,000
-64.5%
134,640
-18.5%
0.00%
Q3 2018$76,000
-10.6%
165,259
-2.0%
0.00%
Q2 2018$85,000
-98.4%
168,670
-92.6%
0.00%
Q1 2018$5,311,000
-14.4%
2,281,379
+4.3%
0.00%
Q4 2017$6,207,000
+12.8%
2,187,203
+13.6%
0.00%
Q3 2017$5,505,000
+15.7%
1,925,320
-0.0%
0.00%
Q2 2017$4,758,000
-70.9%
1,925,401
-57.5%
0.00%
-100.0%
Q1 2017$16,341,000
+6.8%
4,525,051
+4.7%
0.00%0.0%
Q4 2016$15,304,000
-20.2%
4,322,676
-9.0%
0.00%
-50.0%
Q3 2016$19,180,000
-12.1%
4,747,789
-4.5%
0.00%0.0%
Q2 2016$21,829,000
-32.5%
4,972,469
-41.9%
0.00%
-33.3%
Q1 2016$32,362,000
-37.6%
8,561,225
+158.9%
0.00%
-50.0%
Q4 2015$51,855,000
+54.2%
3,307,125
+3.6%
0.01%
+50.0%
Q3 2015$33,635,000
-48.6%
3,191,036
+23.0%
0.00%
-42.9%
Q2 2015$65,413,000
+1.5%
2,593,453
+12.2%
0.01%0.0%
Q1 2015$64,415,000
+44.8%
2,311,250
-5.2%
0.01%
+75.0%
Q4 2014$44,483,000
+34.5%
2,437,241
-4.5%
0.00%0.0%
Q3 2014$33,084,000
-14.3%
2,552,578
+7.9%
0.00%0.0%
Q2 2014$38,597,000
-7.2%
2,364,970
+0.5%
0.00%
-20.0%
Q1 2014$41,579,000
-29.7%
2,352,973
-24.7%
0.01%
+25.0%
Q4 2013$59,147,000
-27.2%
3,126,433
+36.3%
0.00%
-60.0%
Q3 2013$81,273,000
+104.1%
2,293,944
-10.1%
0.01%
+100.0%
Q2 2013$39,820,0002,550,8610.01%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2023
NameSharesValueWeighting ↓
Ridgeback Capital Investments L.P. 1,025,000$24,815,00031.36%
TSP Capital Management Group, LLC 836,342$20,248,0008.80%
Iguana Healthcare Management, LLC 200,000$4,842,0002.76%
First Light Asset Management, LLC 116,096$2,811,0002.38%
SECTORAL ASSET MANAGEMENT INC 2,227,688$53,932,0002.33%
BENNETT LAWRENCE MANAGEMENT L L C/NY 550,735$13,334,0002.05%
Eventide Asset Management 257,000$6,222,0001.92%
Redmile Group, LLC 397,951$9,634,0001.19%
ARDSLEY ADVISORY PARTNERS LP 357,000$8,643,0001.15%
Rhenman & Partners Asset Management AB 90,000$2,179,0000.85%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders